Cytokine and hemopoietic factor endogenous production enhancer a

Details Cytokine and hemopoietic factor endogenous production enhancer a Cytokine and hemopoietic factor endogenous production enhancer a

1996-10-18

2000-12-26

Russel, Jeffrey E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 18, A61K 3806, A61K 3808

Patent

active

061659797

ABSTRACT:
A method of stimulating endogenous production of cytokines and hemopoietic factors by introducing to a mammalian body in need of stimulation of cytokines or hemopoietic factors or both, an effective amount of oxidized glutathione, for a period of time to stimulate said endogenous production to obtain a therapeutic effect. Oxidized glutathione with or without extenders are used in drug forms.

REFERENCES:
patent: 4761399 (1988-08-01), Pilotto et al.
patent: 4871528 (1989-10-01), Tognella et al.
patent: 4927808 (1990-05-01), Kitahara et al.
patent: 4968671 (1990-11-01), Asano et al.
patent: 5248697 (1993-09-01), Wilmore
patent: 5916878 (1999-06-01), Kolobov et al.
Araie, M., et al. (1988) Invest. Ophthalmal. Vis. Sci. 29: 1884-87.
Krieter, H., et al. (1994) Cardiosci. 5: 115-26.
Hansson M., Soderstrom T. The colony stimulating factors. Med Oncol Tumor Pharmacother. 1993. 10(1-2), p. 5-12.
Dillman R.O. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother. 1994 Fal. 9(3). p. 183-209.
Hieber U., Heim M E. Tumor necrosis factor for the treatment of malignancies. Oncology. 1994 Mar-Apr. 51(2) p. 142-53.
Neidhart J.A. Hematopoietic cytokines. Current use in cancer therapy. Cancer. 1993 Dec. 1. 72 (11 Suppl)., p. 3381-6.
Murray H.W. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med. 1994 Nov. 97(5), p. 459-67.
Cirelli R. Tyring S. K. Interferons in human papillomavirus infections. Antiviral Res. 1994 Jul. 24(2-3), p. 191-204.
Sher A. Coffman R.L. Regulation of immunity to parasites by T-cells and T-cell derived cytokines. Annu. Rev. Immunol., 1992. 10. p. 385-409.
Offenstadt G., Guidet B., Staikowsky F. Cytokines and severe infections. Pathol Biol. (Paris). Oct. 1993 41 (8 Pt 2). p. 820-31.
Nelson S. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview. Clin Infect Dis. 1994 Feb. 18, 1994 Suppl 2P S197-204.
Nemunaitis J Use of hematopoietic growth factors in marrow transplantation Curr Opin Oncol Mar. 1994, 6(2). p. 139-45.
Forman A.D. Neurologic complications of cytokine therapy. Oncology (Huntingt). 1994 Apr. 8(4), p. 105-10: discussion 113. 116-7.
Mittelman M., Lessin L. S. Clinical application of recombinant erythropoietin in myelodysplasia. Hematol Clin North Am. 1994 Oct. 8(5), p. 993-1009.
Hack C.E., Ogilvie A.C., Eisele B., Eerenberg A.J., Wagstaff J., Thijs L.G. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. 1993. 19 Suppl 1P S19-28.
Saito M. OK-432, a killed streptococcal preparation, in the treatment of animal and human cancer and its mechanisms of action. Form on i mmunomodulators. Ed. Guenounou M. John Libbey Eurotext. Paris. 1995. p. 1-11,
Barot-Ciorbaru R., Bona C. Immunomodulators from Nocardia opaca Form on immunomodulators. Ed. Guenounou M. John Libbey Eurotext. Paris, 1995. p. 1-11.
Meister A. Anderson M.E. Glutathione. Annu. Rev. Biochem., 1983. 52:711-60.
Beutler E. Nutritional and metabolic aspects of glutathione. Review. Annu. Rev. Nutr., 1989, 9:287.
Textbook of biochemistry: with clinical correlations, Ed. Devlin T.M., 3rd ed. 1992. Wiley-Liss, N.Y. p. 525.
Ehrer J.P., Lund L.G. Cellular reducing equivalents and oxidative strees. Free Radic Biol Med. 1994 Jul. p. 65-75.
Michiels C., Raes M., Toussaint Ol, Remacle J. Importance of Se-glutathione peroxidase, catalase. and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med. 1994 Sep. 17(3), p. 235.48.
Cohen G. Enzymatic
onenzymatic sources of oxyradicals and regulation of antioxidant defenses. Ann NY Acad Sci. 1994 Nov. 17, 738, p. 8-14.
Beckett G.J., Hayes J.D. Glutathione S-transferase: biomedical applications. Advan. Clin. Chem. 1993 vol. 30, p. 281-380.
Droge W., Schultze-Osthoff K., Mihm S., Galter D., Schenk H., Eck H.P., Roth S., Gmunder H. Functions of glutathione and glutathione disulfide in immunology and immunopathology, FASEB J. Nov. 8, 1994 (14) p. 1131-8.
Giugliano D., Ceriello A., Paoliso G. Diabetes mellitus, hypertension, and cardiovascular disease; which role oxidative stress? Metabolism, Mar. 1995 44(3), p. 363-8.
Keusch G.T. Antioxidants in infection, J Nutr Sci Vitaminol (Tokyo), 1993, 39 Suppl P S 23-33.
Sokolovsky M., Wilchek M. Patchornik A. On the synthesis of cystein peptides, J. Amer. Chem. Soc. 1964, Mar. 86(6), p. 1202-6.

Affiliated with

Also associated with

Rating

Cytokine and hemopoietic factor endogenous production enhancer a does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cytokine and hemopoietic factor endogenous production enhancer a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine and hemopoietic factor endogenous production enhancer a will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-994877